Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
Pharmacopsychiatry 2007; 40(6): 292-293
DOI: 10.1055/s-2007-992146
DOI: 10.1055/s-2007-992146
Letter
© Georg Thieme Verlag KG Stuttgart · New York
Pregabalin in Benzodiazepine Withdrawal
Further Information
Publication History
received 25.06.2007
revised 23.07.2007
accepted 24.07.2007
Publication Date:
21 November 2007 (online)

Introduction
Pregabalin is a well tolerated treatment for generalized and social anxiety (licensed only in European countries and not in the USA), epilepsy as well as neuropathic pain [2].
References
- 1 Bateson A. Further potential of the GABA receptor in the treatment of insomnia. Sleep Medicine. 2007; 7 3-9
- 2 Montgomery SA. Pregabalin for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2006; 7 2139-2154
- 3 Rupprecht R, Eser D, Zwanzger P, Möller HJ. GABA-A receptors as targets for novel anxiolytic drugs. World J Biol Psychiatry. 2006; 7 231-237
- 4 Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73 137-150
- 5 Victorri-Vigneau C, Guerlais M, Jolliet P. Abuse, dependency and withdrawal with gabapentin: a first case report. Pharmacopsychiatry. 2007; 40 43-44
- 6 Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today (Barc). 2004; 40 603-619
Correspondence
Dr. med. T. Biermann
Friedrich-Alexander-University of Erlangen-Nuremberg
Department of Psychiatry and Psychotherapy
Schwabachanlage 6-10
91054 Erlangen
Germany
Phone: +49/9131/853 45 97
Fax: +49/9131/853 41 05
Email: teresa.biermann@uk-erlangen.de